What Is the Role of Glucagon-Like Peptide 1 Signaling in the Nervous System and Its Potential Neuroprotective Effects?
P Turcano, R Savica, E Benarroch - Neurology, 2024 - neurology.org
Glucagon-like peptide-1 (GLP-1) is a potent stimulator of insulin secretion, inhibitor of
glucagon secretion, and regulator of energy homeostasis. 1-3 This peptide also inhibits …
glucagon secretion, and regulator of energy homeostasis. 1-3 This peptide also inhibits …
Understanding the link between type 2 diabetes mellitus and Parkinson's disease: role of brain insulin resistance
T Ntetsika, SB Catrina, I Markaki - Neural Regeneration Research, 2025 - journals.lww.com
Type 2 diabetes mellitus and Parkinson's disease are chronic diseases linked to a growing
pandemic that affects older adults and causes significant socio-economic burden …
pandemic that affects older adults and causes significant socio-economic burden …
The use of hypoglycemic drugs in Parkinson's disease: An updated meta-analysis of randomized controlled trials
MVS Sobral, VG Soares, JLML Moreira… - Parkinsonism & related …, 2024 - Elsevier
Introduction Recent studies have demonstrated an association between hypoglycemic
medications and neuroprotective action in neurodegenerative diseases, such as Parkinson's …
medications and neuroprotective action in neurodegenerative diseases, such as Parkinson's …
Negative findings from trials with NLY01 or deferiprone for Parkinson's disease
T Müller, JD Möhr - The Lancet Neurology, 2024 - thelancet.com
3 UK Medicines and Healthcare Products Regulatory Agency. Valproate: review of safety
data and expert advice on management of risks. 2023. https://assets. publishing. service …
data and expert advice on management of risks. 2023. https://assets. publishing. service …
Negative findings from trials with NLY01 or deferiprone for Parkinson's disease–Author's reply
A McGarry - The Lancet Neurology, 2024 - thelancet.com
3 Wu T, Bresee C, Wertheimer J, et al. Liraglutide once daily versus placebo in Parkinson's
disease: a randomized, double-blind, placebo-controlled trial. Mov Disord 2022; 37 (suppl …
disease: a randomized, double-blind, placebo-controlled trial. Mov Disord 2022; 37 (suppl …